SEARCH

SEARCH BY CITATION

References

  • 1
    Muir AJ. The natural history of hepatitis C viral infection. Semin Gastrointest Dis 2000;11:5461.
  • 2
    World Health Organization. Hepatitis C: global prevalence. Wkly Epidemiol Rec 1997;72:3414.
  • 3
    Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:55662.
  • 4
    Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997;26(Suppl. 1):15S20S.
  • 5
    Detre KM, Belle SH, Lomardero M. Liver transplantation for chronic viral hepatitis. Viral Hepatitis Reviews 1997;2:21928.
  • 6
    Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996;24:77889.
  • 7
    Lindsay KL. Therapy of Hepatitis C: Overview. Hepatology 1997;26(Suppl. 1):71S77S.
  • 8
    Poynard T, Bedossa P, Chevallier M, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995;332:145762.
  • 9
    Poynard T, Marcellin P, Lee SS, et al. (for the International Hepatitis Interventional Therapy Group). Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:142632.
  • 10
    McHutchison JG, Gordon SC, Schiff ER, et al. (for the International Hepatitis Interventional Therapy Group). Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:148592.
  • 11
    Davis GL, Esteban-Mur R, Rustgi V, et al. (for the International Hepatitis Interventional Therapy Group). Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339:14939.
  • 12
    Maddrey WC. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C – relapsed and treatment-naïve patients. Semin Liver Dis 1999;19:6775.
  • 13
    Physicians' Desk Reference. REBETRONTM Manufacturer's Information, Schering Plough Corporation. Montvale, NJ: Medical Economics Co, 1999.
  • 14
    Bizollon T, Palazzo U, Ducerf C, et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997;26:4004.
  • 15
    Fischer L, Sterneck M, Valentin-Gamazo C, et al. Treatment of severe recurrent hepatitis C after liver transplantation with ribavirin plus interferon-alpha. Transplant Proc 1999;31:4945.
  • 16
    Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996;334: 81520.
  • 17
    Weisz K, Kreiswirth S, McMeeking M, et al. and the Hepatitis Resource Network. Epoetin use for ribavirin/interferon induced anemia in patients with hepatitis C. (Abstract) Hepatology 1998;28:288A.
  • 18
    Bodenheimer HC, Lindsay KL, Davis GL, et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C. A multicenter trial. Hepatology 1997;26:4737.
  • 19
    Camps J, Garcia N, Riezu-Bog JI, et al. Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon. J Hepatol 1993;19:40812.
  • 20
    DiBisceglie AM, Shindo M, Fong TL, et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 1992;16:64954.
  • 21
    DiBisceglie AM, Conjeevaram HS, Fried MW, et al. Ribavirin as therapy for chronic hepatitis C. Ann Intern Med 1995;123:897903.
  • 22
    Dusheiko G, Main J, Thomas H, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996;25:5918.
  • 23
    Reichard O, Andersson J, Schwarcz R, et al. Ribavirin treatment for chronic hepatitis C. Lancet 1991;337:105861.
  • 24
    Bellobuono A, Mondazzi I, Tempini S, et al. Ribavirin and interferon-α combination therapy vs interferon-α alone in the retreatment of chronic hepatitis C. a randomized clinical trial. J Viral Hepat 1997;4:18591.
  • 25
    Box TD, Boschert ME, Tomason IR, et al. Hemolysis in patients being treated with combination Intron-A/Ribavirin for chronic hepatitis C (CHC) infection. (Abstract) Hepatology 1998;28:574A.
  • 26
    Chemello L, Cavalleto L, Bernardinello E, et al. The effect of interferon alfa and ribavirin combination therapy in naïve patients with chronic hepatitis C. J Hepatol Suppl 1995; 23(Suppl. 2): 812.
  • 27
    Kakumu S, Yoshioka K, Wakita T, et al. A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C. Gastroenterology 1993; 105:50712.
  • 28
    Perasso A, Testino G, Ansaldi F, et al. R-interferon alpha-2b/ribavirin combined therapy followed by low-dose r-interferon alfa-2b in chronic hepatitis C interferon nonresponders. Hepatology 1999;29: 2978.
  • 29
    Schwarcz R, Ando Y, Sonnerborg A, et al. Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience. J Hepatol 1995;23 (Suppl. 2):1721.
  • 30
    Van Leeuwen DJ, Langer R, Abrams GA, et al. Initial experiences with interferon and ribavirin for hepatitis C; tolerability of treatment in an academic center. (Abstract) Hepatology 1998;28: 716A.
  • 31
    Barbaro G, Di Lorenzo G, Belloni G, et al. Interferon alpha-2b and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after interferon-alpha therapy: a randomized trial. Am J Med 1999;107:1128.
  • 32
    Lai MY, Kao JH, Yang PM, et al. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996;111:130712.
  • 33
    Pol S, Couzigou P, Bourliere M, et al. and a multicenter study group under the coordination of the Necker Hospital, Paris, France. A randomized trial of ribavirin and interferon-α vs. interferon-α alone in patients with chronic hepatitis C who were non-responders to a previous treatment. J Hepatol 1999;31:17.
  • 34
    Reichard O, Norkrans G, Fryden A, et al. for the Swedish Study Group. Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C. Lancet 1998;351:837.
  • 35
    Sostegni R, Ghisetti V, Pittaluga F, et al. Sequential versus concomitant administration of ribavirin and interferon alfa n-3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized controlled trial. Hepatology 1998;28:3416.
  • 36
    Schalm SW, Hansen BE, Chemello L, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. J Hepatol 1997;26:9616.
  • 37
    Drug Topics (Trademark). Red Book (Trademark). Montvale, NJ: Medical Economics Co., Inc. 1999, 1999.
  • 38
    drugstore.com. [cited October 5]. Available from: http://www.drugstore.com. First accessed in 1999.
  • 39
    McEvoy G. AHFS Drug Information ‘99. Bethesda, MD: American Society of Health-System Pharmacists, 1999.
  • 40
    Salmeron J, Ruiz-Extremera A, Torres C, et al. Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: a randomized trial. Liver 1999;19:27580.
  • 41
    Bonkovsky HL, Stefancyk D, Leclair P, et al. Low doses (600 mg/d) of ribavirin are superior to high doses (1000–1200 mg/d) with interferon for chronic hepatitis C. results of a controlled, randomized, multicenter trial. Hepatology 1999;30(4 part 2):265A.
  • 42
    Wong JB, Poynard T, Ling MH, et al. on behalf of the International Hepatitis Interventional Therapy (IHIT) Group. Cost-effectiveness of 24 or 48 weeks of interferon α-2b alone or with ribavirin as initial treatment of chronic hepatitis C. Am J Gastroenterol 2000;95(6):152430.
  • 43
    Wong JB, Davis GL, Pauker SG. Cost-effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis C. Am J Med 2000;108 (5):36673.
  • 44
    Younossi ZM, Singer ME, McHutchison JG, et al. Cost effectiveness of interferon α2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 1999;30:131824.
  • 45
    NDA, 20–903. Center for Drug Evaluation and Research. Food and Drug Administration. U.S. Department of Health and Human Services. June–July, 1998.
  • 46
    Lyons MF, Coddou AK, Varon CM, et al. Side effect profile of combination with interferon alpha-2b (IFN) and ribavirin in a community-based clinical trial. Gastroenterology 1999;116 (4 part 2): A77.